Skin Infection News and Research

RSS

Optimer, Cubist sign deal to market DIFICID for CDI treatment in the U.S.

Optimer Pharmaceuticals, Inc. and Cubist Pharmaceuticals, Inc. today announced the signing of an exclusive two-year co-promotion agreement to market DIFICID, in the United States.

6 Apr 2011

New ‘nanotech’ weapon against drug-resistant superbugs

Scientists at the Institute of Bioengineering and Nanotechnology (IBN) and IBM Research – Almaden have developed the first biodegradable polymer nanoparticles to combat drug-resistant superbugs, such as Methicillin-Resistant Staphylococcus aureus (MRSA). These nanoparticles can selectively kill the bacteria without destroying healthy red blood cells, and being biodegradable, have great potential to treat infectious diseases in the body. This was reported today in the leading scientific journal, Nature Chemistry [(2011) DOI: 10.1038/nchem.1012].

3 Apr 2011

Study finds significant increase in MRSA infections during summer, autumn months

A new study from Rhode Island Hospital has found a significant increase in the occurrence of methicillin-resistant Staphylococcus aureus infections in the summer and autumn months.

25 Mar 2011

Research: Used instrument can pose dangerous health risk in children

Research has shown that playing a musical instrument can help nourish, cultivate, and increase intelligence in children, but playing a used instrument also can pose a potentially dangerous health risk.

15 Mar 2011

Proper wound care may treat skin infections effectively than antibiotics in children with MRSA

When it comes to curing skin infected with the antibiotic-resistant bacterium MRSA, timely and proper wound cleaning and draining may be more important than the choice of antibiotic, according to a new Johns Hopkins Children's Center study. The work is published in the March issue of Pediatrics.

21 Feb 2011

RF-induced heat therapy could help treat common parasitic skin infection

Scientists are hoping that heat therapy could eventually replace a complex drug regimen as the first-line treatment of a parasitic skin infection common in tropical and subtropical regions of the world.

11 Feb 2011

Dermatologists urge athletes to be aware of most common skin infections

Team sports have a long history of fostering cooperation, camaraderie and a healthy competitive spirit among athletes. But the closeness that brings athletes together also can create an environment for a host of contagious skin infections. Now, dermatologists are urging teammates and coaches to be aware of the most common skin conditions caused by bacteria, viruses and fungi that occur in athletes and educating them on how to prevent a widespread outbreak.

5 Feb 2011

IDSA releases MRSA treatment guidelines

Physicians now have help in their battle against methicillin resistant Staphylococcus aureus (MRSA), a potentially deadly infection that initially was limited to hospitals and health care facilities but has become a growing problem in healthy children and adults. The Infectious Diseases Society of America (IDSA) has released its first guidelines for the treatment of increasingly common MRSA infections.

7 Jan 2011

New research sheds light on complex regulatory pathways for effective innate immune system

New research by scientists at the University of California, San Diego School of Medicine and Skaggs School of Pharmacy and Pharmaceutical Sciences reveals that the immune system has an effective backup plan to protect the body from infection when the "master regulator" of the body's innate immune system fails.

21 Dec 2010

NovaBay Pharmaceuticals, Galderma expand their multi-year collaboration agreement

NovaBay Pharmaceuticals, Inc., a clinical stage biotechnology company developing first-in-class, anti-infective compounds for the treatment and prevention of antibiotic-resistant infections, and Galderma, a global leading pharmaceutical company dedicated exclusively to the field of dermatology, announce the expansion of their multi-year collaboration agreement. Based on positive data assessing the activity of NovaBay's Aganocide compounds against impetigo, Galderma has agreed to exercise its option for this indication.

6 Dec 2010

FDA approves CUBICIN 2-minute IV injection for MRSA skin infections, bacteremia

Cubist Pharmaceuticals, Inc. today announced that its currently-marketed antibiotic, CUBICIN (daptomycin for injection), has been approved by the U.S. Food & Drug Administration (FDA) for once-a-day dosing as a 2-minute intravenous (IV) injection.

2 Dec 2010

Statins activate bacterial-killing properties of white blood cells

Widely prescribed for their cholesterol-lowering properties, recent clinical research indicates that statins can produce a second, significant health benefit: lowering the risk of severe bacterial infections such as pneumonia and sepsis.

18 Nov 2010

NovaBay third quarter net loss increases to $1.6 million

12 Nov 2010

Scientists to present new findings from NIAID-funded research at ACAAI Annual Meeting

The 2010 Annual Meeting of the American College of Allergy, Asthma & Immunology (ACAAI) brings together leading allergists and immunologists from around the world.

12 Nov 2010

FDA new approvals, antibiotic and neurological drugs

Two new drugs have gained approval from the US Food and Drug Administration (FDA) – one is an antibiotic from Forest Labs and the other a first-time treatment for a neurological disorder developed by Avanir Pharmaceuticals. Another waiting for approval is Biodel's fast-acting insulin Linjeta. On the other hand seven new drugs got rejected including a diabetes drug from Amylin Pharmaceuticals and weight-loss drugs from Arena Pharmaceuticals and Vivus, respectively.

31 Oct 2010

Teflaro receives FDA approval for treatment of bacterial infections

The U.S. Food and Drug Administration today approved Teflaro (ceftaroline fosamil), an injectable antibiotic to treat adults with community acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI), including methicillin-resistant Staphylococcus aureus (MRSA).

30 Oct 2010

Glaxo to pay $750 million in defective drug settlement

GlaxoSmithKline Plc, one of the world’s largest pharmaceutical companies, has agreed to pay $750 million to settle a U.S. government false-claims lawsuit over the sale of defective drugs. The lawsuit first filed in 2004 by Cheryl D. Eckard, a former global quality assurance manager for the London-based company came to a settlement finally. Eckard, 51, said, “This is not something I wanted to do, but because of patient safety it was necessary.” Being the one to bring this to notice she would receive $96 million from the settlement money. She had warned the company earlier but was fired because of her efforts.

26 Oct 2010

NovaBay delivers two poster presentations on Aganocide compounds at IDSA Annual Meeting

NovaBay Pharmaceuticals, Inc. a clinical stage biotechnology company developing first-in-class, anti-infective compounds for the treatment and prevention of antibiotic-resistant infections, delivered two poster presentations on its compounds at the 48th Annual Meeting of the Infectious Diseases Society of America (IDSA) in Vancouver, Canada.

25 Oct 2010

Vancomycin beneficial for managing patients hospitalized with cellulits

Patients admitted to the hospital for the common bacterial skin infection cellulitis should be treated as a first line of defense with the potent antibiotic drug vancomycin rather than other antibiotics such as penicillin, according to a Henry Ford Hospital study.

25 Oct 2010

Forest Laboratories second quarter net sales increase 7.7% to $1,037.3 million

Forest Laboratories, Inc., an international pharmaceutical manufacturer and marketer, announced that diluted earnings per share equaled $1.00 in the second quarter of fiscal 2011.

19 Oct 2010